DE69111798D1 - 19f-markierte verbindungen zur verwendung als nmr-bilderzeugungs- und spektroskopiermittel. - Google Patents

19f-markierte verbindungen zur verwendung als nmr-bilderzeugungs- und spektroskopiermittel.

Info

Publication number
DE69111798D1
DE69111798D1 DE69111798T DE69111798T DE69111798D1 DE 69111798 D1 DE69111798 D1 DE 69111798D1 DE 69111798 T DE69111798 T DE 69111798T DE 69111798 T DE69111798 T DE 69111798T DE 69111798 D1 DE69111798 D1 DE 69111798D1
Authority
DE
Germany
Prior art keywords
perfluorocarbon emulsion
tissue
subject
spin
oxygen tension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69111798T
Other languages
English (en)
Other versions
DE69111798T2 (de
Inventor
Peter Antich
Padmakar Kulkarni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Application granted granted Critical
Publication of DE69111798D1 publication Critical patent/DE69111798D1/de
Publication of DE69111798T2 publication Critical patent/DE69111798T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/806—Electrical property or magnetic property
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
DE69111798T 1990-02-21 1991-02-21 19f-markierte verbindungen zur verwendung als nmr-bilderzeugungs- und spektroskopiermittel. Expired - Fee Related DE69111798T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/482,879 US5236694A (en) 1990-02-21 1990-02-21 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents
PCT/US1991/001150 WO1991012824A2 (en) 1990-02-21 1991-02-21 19f labelled compounds as nmr imaging and spectroscopy agents

Publications (2)

Publication Number Publication Date
DE69111798D1 true DE69111798D1 (de) 1995-09-07
DE69111798T2 DE69111798T2 (de) 1995-11-30

Family

ID=23917811

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69111798T Expired - Fee Related DE69111798T2 (de) 1990-02-21 1991-02-21 19f-markierte verbindungen zur verwendung als nmr-bilderzeugungs- und spektroskopiermittel.

Country Status (9)

Country Link
US (3) US5236694A (de)
EP (1) EP0517788B1 (de)
JP (1) JPH05506432A (de)
AT (1) ATE125712T1 (de)
AU (1) AU641233B2 (de)
CA (1) CA2075953A1 (de)
DE (1) DE69111798T2 (de)
ES (1) ES2075433T3 (de)
WO (1) WO1991012824A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236694A (en) * 1990-02-21 1993-08-17 The Board Of Regents, The University Of Texas System 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
GB9216843D0 (en) * 1992-08-07 1992-09-23 Cancer Res Inst Contrast agents for medical imaging
US5468467A (en) * 1993-04-23 1995-11-21 Bracco International B.V. Methods for the in vivo measurement of the concentration of non-imaging nmr-detectable xenobiotic compounds
DE4318369C1 (de) * 1993-05-28 1995-02-09 Schering Ag Verwendung von makrocyclischen Metallkomplexen als Temperatursonden
GB9325330D0 (en) * 1993-12-10 1994-02-16 Univ Toronto Fluorocyclodextrin drug delivery system
US5807978A (en) * 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
EP0831935A4 (de) * 1995-06-07 2001-08-29 Mallinckrodt Medical Inc Gasförmige ultraschallkontrastmittel und dazugehörige verfahren
US5678548A (en) * 1995-07-20 1997-10-21 The United States Of America As Represented By The Department Of Health And Human Services System and method for performing in vivo imaging and oxymetry and FT microscopy by pulsed radiofrequency electron paramagnetic resonance
US5753207A (en) * 1995-08-21 1998-05-19 Beth Israel Deaconess Medical Center, Inc. Use of paramagnetic compounds to measure temperature and pH in vivo
US5828216A (en) * 1996-08-19 1998-10-27 The United States Of America As Represented By The Department Of Health And Human Services Gated RF preamplifier for use in pulsed radiofrequency electron paramagnetic resonance and MRI
AT409929B (de) * 1997-03-07 2002-12-27 Tritthart Helmut A Dr Polymere-infusionslösung zur anwendung bei der diagnose von tumoren, gegebenenfalls zu deren behandlung
US6419174B1 (en) * 2000-08-18 2002-07-16 J. M. Huber Corporation Abrasive compositions and methods for making same
US6574497B1 (en) 2000-12-22 2003-06-03 Advanced Cardiovascular Systems, Inc. MRI medical device markers utilizing fluorine-19
NO20015802D0 (no) * 2001-11-28 2001-11-28 Amersham Health As Diagnostisk metode
US7030208B2 (en) 2002-04-11 2006-04-18 Carbomer, Inc. Biocompatible materials and probes
JP2005522495A (ja) 2002-04-11 2005-07-28 カルボマー インク 新規な糖尿病イメージングプローブ
US7090829B2 (en) * 2002-04-11 2006-08-15 Carbomer, Inc. Imaging probes
WO2004078990A1 (en) * 2003-02-28 2004-09-16 Carbomer, Inc. Halogenated emulsans
EP1713513B1 (de) 2004-01-16 2014-06-04 Carnegie Mellon University Zell-markierung für kernspin-techniken
MX2007005507A (es) * 2004-11-12 2008-03-13 Neurochem Int Ltd Metodos y composiciones fluoradas para el tratamiento de padecimientos relacionados con amiloides.
DE102005005704B4 (de) * 2005-02-03 2010-08-12 Leibniz-Institut Für Festkörper- Und Werkstoffforschung Dresden E.V. Verwendung von Partikeln für die Ermittlung der lokalen Temperatur in organischen und nichtorganischen Körpern
EP2010646A2 (de) * 2006-04-14 2009-01-07 Carnegie Mellon University Zellbeschriftung und -quantifizierung für nukleare magnetresonanzverfahren
US20070258886A1 (en) * 2006-04-14 2007-11-08 Celsense Inc. Methods for assessing cell labeling
GB0711662D0 (en) * 2007-06-15 2007-07-25 Cancercure As Magnetic resonance guided cancer treatment system
EP2170975B1 (de) * 2007-07-10 2018-05-02 Carnegie Mellon University Zusammensetzungen und verfahren zur herstellung von zellmarkern für kernresonanztechniken
US8093060B2 (en) * 2008-02-28 2012-01-10 Canon Kabushiki Kaisha Multisite phosphorylated peptide (protein) recognizing compound and detection method, imaging method, alzheimer's disease diagnosing method and reagent kit using the same
CA2723171C (en) * 2008-05-02 2018-03-27 Celsense, Inc. Emulsion compositions and methods for nuclear magnetic resonance and other imaging
WO2011013038A2 (en) 2009-07-31 2011-02-03 Koninklijke Philips Electronics N.V. Perfluoro compounds for use in imaging
CA2820754A1 (en) * 2010-12-10 2012-06-14 Ralf Guenther Aptamer labelled with f-19 nucleus for targeted molecular imaging by mri
WO2012142670A1 (en) * 2011-04-20 2012-10-26 The University Of Queensland Nuclear magnetic resonance agent
JP6234064B2 (ja) * 2012-05-23 2017-11-22 キヤノン株式会社 重合体、前記重合体を用いた核磁気共鳴分析用または磁気共鳴イメージング用の造影剤、化合物、前記重合体を用いた核磁気共鳴分析方法および磁気共鳴イメージング方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4817750B1 (de) * 1970-12-29 1973-05-31
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4741900A (en) * 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4640833A (en) * 1983-02-28 1987-02-03 Adamantech, Inc. Use of perfluorobromoalkyl ethers as X-ray contrast agents
US4586511A (en) * 1983-03-04 1986-05-06 Children's Hospital Medical Center Methods and compositions for detecting and imaging a gas in an animal by nuclear magnetic resonance
US4558279A (en) * 1983-03-07 1985-12-10 University Of Cincinnati Methods for detecting and imaging a temperature of an object by nuclear magnetic resonance
US4612185A (en) * 1984-10-15 1986-09-16 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
SE465907B (sv) * 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
US4639364A (en) * 1984-11-14 1987-01-27 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
US4865836A (en) * 1986-01-14 1989-09-12 Fluoromed Pharmaceutical, Inc. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US5080885A (en) * 1986-01-14 1992-01-14 Alliance Pharmaceutical Corp. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US5141739A (en) * 1986-07-03 1992-08-25 Advanced Magnetics, Inc. Delivery of x-ray contrast agents using receptor mediated endocytosis
JP2514340B2 (ja) * 1986-11-26 1996-07-10 森 武貞 修飾抗体
US4838274A (en) * 1987-09-18 1989-06-13 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance imaging
US4914210A (en) * 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
AU2803289A (en) * 1987-10-27 1989-05-23 Fluoromed Pharmaceutical, Inc. Method of using fluorocarbons in nuclear magnetic resonance imaging
GB8801646D0 (en) * 1988-01-26 1988-02-24 Nycomed As Chemical compounds
DE3834704A1 (de) * 1988-10-07 1990-06-07 Schering Ag Fluorsubstituierte benzolderivate
US5116599A (en) * 1989-07-31 1992-05-26 Johns Hopkins Univ. Perfluoro-t-butyl-containing compounds for use in fluorine-19 nmr and/or mri
US5236694A (en) * 1990-02-21 1993-08-17 The Board Of Regents, The University Of Texas System 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents
US5068098A (en) * 1990-06-11 1991-11-26 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance spectroscopy
US5196348A (en) * 1990-06-11 1993-03-23 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance spectroscopy of biopsied tissue

Also Published As

Publication number Publication date
US5397562A (en) 1995-03-14
AU641233B2 (en) 1993-09-16
EP0517788A1 (de) 1992-12-16
JPH05506432A (ja) 1993-09-22
WO1991012824A3 (en) 1992-02-20
DE69111798T2 (de) 1995-11-30
AU7453991A (en) 1991-09-18
US5422094A (en) 1995-06-06
ATE125712T1 (de) 1995-08-15
WO1991012824A2 (en) 1991-09-05
CA2075953A1 (en) 1991-08-22
EP0517788B1 (de) 1995-08-02
ES2075433T3 (es) 1995-10-01
US5236694A (en) 1993-08-17

Similar Documents

Publication Publication Date Title
DE69111798D1 (de) 19f-markierte verbindungen zur verwendung als nmr-bilderzeugungs- und spektroskopiermittel.
Golman et al. Dynamic in vivo oxymetry using overhauser enhanced MR imaging
US6370415B1 (en) Magnetic resonance imaging method
Merboldt et al. Decrease of glucose in the human visual cortex during photic stimulation
Gruber et al. Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H-MRS at 3 Tesla
Matsumoto et al. MR assessment of changes of tumor in response to hyperbaric oxygen treatment
Liu et al. Assessment of cerebral pO2 by EPR oximetry in rodents: effects of anesthesia, ischemia, and breathing gas
DE69536022D1 (de) Bilderzeugung mittels magnetischer kernresonanz unter einwirkung hyperpolarisierter edelgase
Komoroski et al. In Vivo NMR spectroscopy of lithium‐7 in humans
US5468467A (en) Methods for the in vivo measurement of the concentration of non-imaging nmr-detectable xenobiotic compounds
Rupreht et al. Evaluation of the tibial tunnel after intraoperatively administered platelet‐rich plasma gel during anterior cruciate ligament reconstruction using diffusion weighted and dynamic contrast‐enhanced MRI
Jezzard et al. An in vivo model for functional MRI in cat visual cortex
Vallatos et al. Multiple boli arterial spin labeling for high signal‐to‐noise rodent brain perfusion imaging
Garbow et al. A simple, robust hardware device for passive or active respiratory gating in MRI and MRS experiments
Crémillieux et al. Online quantification of lactate concentration in microdialysate during cerebral activation using 1H-MRS and sensitive NMR microcoil
Lambers et al. Fiber-based lactate recordings with fluorescence resonance energy transfer sensors by applying an magnetic resonance-informed correction of hemodynamic artifacts
Felber et al. Localized proton and phosphorus magnetic resonance spectroscopy following electroconvulsive therapy
BR8700902A (pt) Processo de diagnostico de cancer em um paciente vivo,processo para deteccao de cancer e espectrometro de nmr
Pohmann et al. Fast perfusion measurements in rat skeletal muscle at rest and during exercise with single‐voxel FAIR (flow‐sensitive alternating inversion recovery)
CA2327733C (en) Use of a hyperpolarized gas for mri detection of regional variations in oxygen uptake from the lungs
ATE395611T1 (de) Pulsfolge, kernspinresonanztomograph und bildgebungsverfahren
Venkatasubramanian et al. Characterization of the cerebral distribution of general anesthetics in vivo by two‐dimensional 19F chemical shift imaging
WO1999053332A1 (en) Use of a hyperpolarized gas for mri detection of regional variations in oxygen uptake from the lungs
van Zijl et al. Measurement of cerebral blood flow by volume‐selective 19F NMR spectroscopy
Imai et al. MR imaging of mouse lung using hyperpolarized 3He: image acquisition and T1 estimation under spontaneous respiration

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee